Treatment troubleshooting

My GLP-1 is not working — why?

A GLP-1 that "is not working" is rarely a true non-response. The far more common explanations are dose, time, or hidden contributors. Here is the clinical framework.

Direct answer

Roughly 80–90% of "GLP-1 not working" cases are explained by under-dosing, insufficient time on the medication, undertreated comorbidities (sleep, alcohol, stress, medications), or unrealistic week-to-week expectations. True pharmacologic non-response is uncommon and typically managed by switching agents.

What "not working" usually means

Patients usually describe one of three patterns:

No weight loss at all after 4–8 weeks at the starting dose.
Initial loss, then a stall at a dose that previously worked.
Loss is real but slower than expected compared to clinical trial averages.

The first two are usually fixable. The third is often not actually a problem — trial averages are averages.

Why does this happen?

The most common reasons, in order of clinical frequency:

Dose is too low. The starting dose of semaglutide (0.25 mg) and tirzepatide (2.5 mg) is for tolerance, not for weight loss. Real weight effects begin at therapeutic doses.
Not enough time. The titration schedule is 16+ weeks. Judging response at week 4 is premature.
Sleep, alcohol, and medications. Sleep <6 hours, regular alcohol, and weight-promoting medications (SSRIs, antipsychotics, beta-blockers, steroids, insulin, sulfonylureas) blunt response.
Inadequate protein and resistance training. Lean mass loss slows metabolism and stalls progress.
Compounding or storage problems. Improper storage of compounded medication can reduce potency.
True non-response. Roughly 10–15% of patients lose <5% on semaglutide; switching to tirzepatide often resolves this.

Biological reasons response can be blunted

Insulin resistance and hyperinsulinemia — drives storage and resists fat mobilization.
Hypothyroidism — undertreated thyroid disease slows metabolic rate.
High cortisol from chronic stress or sleep apnea — promotes visceral fat.
Hormonal transitions — perimenopause and menopause blunt response. More.
Genetic variation in GLP-1 receptor signaling — a small subset of patients respond better to dual GIP/GLP-1 agonists like tirzepatide.

Behavioral patterns that mask response

Liquid calories. Smoothies, sweetened coffees, and alcohol bypass the satiety effect.
Compensatory eating on weekends or "off" days that erases a weekly deficit.
Skipping doses — even one missed weekly dose materially reduces drug exposure.
Aggressive scale watching. Daily fluctuations of 2–5 lb are normal. Weekly averages are the signal.

How clinicians fix a stalled response

The evidence-based response sequence:

Confirm titration. Most patients need to reach 1.7 mg or 2.4 mg semaglutide, or 7.5–15 mg tirzepatide, before judging response.
Audit lifestyle inputs. Sleep, alcohol, protein intake, resistance training, and medication review.
Lab workup if no response at therapeutic dose. TSH, fasting insulin, A1C, cortisol if indicated.
Switch agents. Tirzepatide produces additional weight loss in semaglutide non-responders in studies and clinical practice.
Reassess timeline. Goal weight is reached over 12–18 months, not 12 weeks.

For dose details, see semaglutide and tirzepatide.

Common misconceptions

MythIf a GLP-1 is going to work, I will see it in week one.

What clinicians seeWeek-one effects are usually nausea and modest appetite reduction. Weight loss accelerates after the first month at therapeutic dose.

MythStalling means the medication is failing.

What clinicians seeStalls are biological — the body defends weight at every new lower setpoint. They almost always resolve with patience or a dose increase.

MythI should eat as little as possible while it is working.

What clinicians seeAggressive restriction triggers metabolic adaptation and lean mass loss, which slows progress.

Frequently asked questions

How long should I wait before deciding it is not working?

At least 12–16 weeks at a therapeutic dose, not the starting dose. Most clinicians want to see at least 5% loss by month 4 on a full dose.

Should I increase my dose if I am not losing?

Increases are guided by clinical response and tolerance. Talk to your clinician — do not self-titrate.

Can I switch from semaglutide to tirzepatide?

Yes. Many patients who plateau on semaglutide lose additional weight after switching to tirzepatide, since it acts on both GLP-1 and GIP receptors.

Does alcohol blunt GLP-1 results?

Yes — alcohol adds calories without satiety, disrupts sleep, and impairs liver glucose handling. Read more.

Could my other medications be the problem?

Possibly. SSRIs, antipsychotics, beta-blockers, steroids, insulin, and sulfonylureas commonly promote weight gain. Ask your clinician for a review.

Is a slow loser still a winner?

Yes. Even 5–10% sustained weight loss meaningfully reduces cardiometabolic risk.

Educational summary

If a GLP-1 is not working, the cause is rarely the molecule. Under-dosing, insufficient time, sleep, alcohol, weight-promoting medications, and unaddressed thyroid or insulin issues account for the majority of non-response. A structured workup — lifestyle audit, dose escalation, and if needed, switching from semaglutide to tirzepatide — resolves most of these cases. See also: GLP-1 plateau · Breaking a plateau.

See if a GLP-1 plan fits you

U.S.-licensed clinicians review every intake. Membership includes the medication, clinician access, and ongoing care.

Choose a plan

References

Wilding JPH et al. STEP 1 trial. NEJM 2021;384:989–1002.
Jastreboff AM et al. SURMOUNT-1 trial. NEJM 2022;387:205–216.
Frías JP et al. SURPASS-2: Tirzepatide vs semaglutide. NEJM 2021;385:503–515.
AACE Comprehensive Clinical Practice Guidelines for Obesity, 2016 (with updates).

Editorial standards

Reviewed against current GLP-1 prescribing labeling, AACE/Endocrine Society obesity guidelines, ADA Standards of Care, and peer-reviewed clinical literature. Educational content — not a substitute for individualized medical advice. See our medical review policy.